ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Division Spotlight
Reactor Physics
The division's objectives are to promote the advancement of knowledge and understanding of the fundamental physical phenomena characterizing nuclear reactors and other nuclear systems. The division encourages research and disseminates information through meetings and publications. Areas of technical interest include nuclear data, particle interactions and transport, reactor and nuclear systems analysis, methods, design, validation and operating experience and standards. The Wigner Award heads the awards program.
Meeting Spotlight
ANS Student Conference 2025
April 3–5, 2025
Albuquerque, NM|The University of New Mexico
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Feb 2025
Jul 2024
Latest Journal Issues
Nuclear Science and Engineering
March 2025
Nuclear Technology
Fusion Science and Technology
February 2025
Latest News
Colin Judge: Testing structural materials in Idaho’s newest hot cell facility
Idaho National Laboratory’s newest facility—the Sample Preparation Laboratory (SPL)—sits across the road from the Hot Fuel Examination Facility (HFEF), which started operating in 1975. SPL will host the first new hot cells at INL’s Materials and Fuels Complex (MFC) in 50 years, giving INL researchers and partners new flexibility to test the structural properties of irradiated materials fresh from the Advanced Test Reactor (ATR) or from a partner’s facility.
Materials meant to withstand extreme conditions in fission or fusion power plants must be tested under similar conditions and pushed past their breaking points so performance and limitations can be understood and improved. Once irradiated, materials samples can be cut down to size in SPL and packaged for testing in other facilities at INL or other national laboratories, commercial labs, or universities. But they can also be subjected to extreme thermal or corrosive conditions and mechanical testing right in SPL, explains Colin Judge, who, as INL’s division director for nuclear materials performance, oversees SPL and other facilities at the MFC.
SPL won’t go “hot” until January 2026, but Judge spoke with NN staff writer Susan Gallier about its capabilities as his team was moving instruments into the new facility.
Martha Hultqvist, Irena Gudowska
Nuclear Technology | Volume 168 | Number 1 | October 2009 | Pages 123-127
Dose/Dose Rate | Special Issue on the 11th International Conference on Radiation Shielding and the 15th Topical Meeting of the Radiation Protection and Shielding Division (Part 1) / Radiation Protection | doi.org/10.13182/NT09-A9111
Articles are hosted by Taylor and Francis Online.
The mathematical anthropomorphic phantoms EVA-HIT and ADAM-HIT have been used in the Monte Carlo code SHIELD-HIT07 for simulations of lung tumor and prostate irradiation with light ions. Calculations were performed for 1H, 7Li, and 12C beams of energies in the range of 80 to 330 MeV/u. The secondary doses to organs, due to scattered primary ions and secondary particles produced in the phantoms, were studied taking into account the contribution from secondary neutrons, secondary protons, pions, and heavier fragments from helium to calcium. The doses to organs per dose to target (tumor) are of the order of 10-6 to 10-1 mGy Gy-1 and decrease with increasing distance from the target. In general the organ dose per target dose increases with increasing Z of the primary particle; however, for lighter primary ions (Z 3) and for organs close to the target, scattered primary particles show a nonnegligible dose contribution.
